SCHEMBL4332464

SCHEMBL4332464

COc1cc(C(=O)NCc2cc3ccccc3o2)cc2c(-c3cccc(F)c3)n[nH]c12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK1D P48730 1/20 0.41
HPGD P15428 2/20 0.41
HSD17B10 Q99714 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
ROCK2 O75116 3/20 0.40
ROCK1 Q13464 3/20 0.40
NTRK1 P04629 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
MAPT P10636 2/20 0.40
MEN1 O00255 1/20 0.40
CACNA1B Q00975 1/20 0.40
APBA1 Q02410 1/20 0.40
KMT2A Q03164 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
PKM P14618 1/20 0.40
CYP2C19 P33261 1/20 0.40
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4332115 0.90 CSNK1D (0.43) CSNK1DHPGDHSD17B10SMN1; SMN2MAPT
SCHEMBL4340581 0.89 CSNK1D (0.42) CSNK1DHPGDHSD17B10SMN1; SMN2ROCK2
SCHEMBL4348128 0.86 ALDH1A1 (0.45) HPGDHSD17B10SMN1; SMN2ROCK2ROCK1
SCHEMBL4334956 0.85 HPGD (0.53) HPGDHSD17B10SMN1; SMN2L3MBTL1MAPT
SCHEMBL4341438 0.81 TTK (0.51) HPGDHSD17B10SMN1; SMN2ROCK2ROCK1
SCHEMBL4334043 0.79 PTGDR2 (0.42) CSNK1DHPGDHSD17B10SMN1; SMN2ROCK2
SCHEMBL4332230 0.78 MAPT (0.44) SMN1; SMN2ROCK2ROCK1NTRK1MAPT
SCHEMBL4340568 0.77 HPGD (0.56) HPGDSMN1; SMN2ROCK2L3MBTL1MEN1
SCHEMBL4333958 0.77 HPGD (0.56) HPGDSMN1; SMN2ROCK2L3MBTL1MEN1
SCHEMBL2861181 0.76 MAP2K4 (0.51) HPGDNTRK1KDM4EALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7776890-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-17 US disclosed
US-7776890-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-17 US disclosed
EP-1380576-B1 1H-INDAZOLE COMPOUNDS INHIBITING JNK EISAI R&D MAN CO LTD (JP) 2009-11-25 EP disclosed
US-20090203691-A1 Novel 1H-indazole compounds OINUMA HITOSHI 2009-08-13 US disclosed
US-20090203691-A1 Novel 1H-indazole compounds OINUMA HITOSHI 2009-08-13 US disclosed
US-7541376-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-06-02 US disclosed
US-20050282880-A1 Novel 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2005-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203691-A1 Novel 1H-indazole compounds MAPK1, MAPK3, MAPK13 CSNK1D 134/4885HPGD 1817/4885HSD17B10 1699/4885
US-20050282880-A1 Novel 1H-indazole compounds MAPK1, MAPK3, MAPK13 CSNK1D 134/4885HPGD 1817/4885HSD17B10 1699/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.